Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer (CheckMate649)

Trial Profile

Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer (CheckMate649)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Apr 2018

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Capecitabine; Capecitabine; Fluorouracil; Fluorouracil; Folinic acid; Folinic acid; Oxaliplatin; Oxaliplatin
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms CheckMate649
  • Sponsors Bristol-Myers Squibb; Ono Pharmaceutical
  • Most Recent Events

    • 12 Apr 2018 Planned number of patients changed to 1749.
    • 28 Mar 2018 Planned number of patients changed from 1266 to 1349.
    • 12 Feb 2018 Planned End Date changed from 11 Oct 2020 to 6 Oct 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top